Cormorant Asset Management, LLC Buys InflaRx NV, ChemoCentryx Inc, Galapagos NV, Sells Tesaro Inc, Dicerna Pharmaceuticals Inc, Mirati Therapeutics Inc

• New Purchases: CCXI, GLPG, AUTL, ATRA, MYOV, GOSS, DTIL,
• Added Positions: IFRX, ASND, CRSP, SRPT, ALLK, BHVN, KURA, YMAB, TCDA, BPMC, RUBY, EIDX,
• Reduced Positions: MRTX, AVRO, ARGX, KNSA, INCY, APLS, ANAB, SLDB, ZLAB, NBIX, SAGE, MYOK, RCKT, RETA, KZR, ZGNX, ARNA, PRNB, INSP, NKTR, AMRN, ARRY, QTNT, XFOR, RARX, SRRK, COLL, ABEO, BOLD, ITRM, HRTX, ACRS, XLRN, AXNX,
• Sold Out: TSRO, DRNA, TBPH, GTHX, REPL, CTMX, CFRX, MGTX, SGMO, QTRX, ARQL,

For the details of Cormorant Asset Management, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/cormorant+asset+management%2C+llc/current-portfolio/portfolio

1. InflaRx NV (IFRX) - 2,590,000 shares, 6.85% of the total portfolio. Shares added by 75.58%
2. SPDR Series Trust S&P Biotech (XBI) - 925,000 shares, 5.86% of the total portfolio.
3. Mirati Therapeutics Inc (MRTX) - 1,075,000 shares, 5.52% of the total portfolio. Shares reduced by 38.63%
4. Ascendis Pharma A/S (ASND) - 600,000 shares, 4.94% of the total portfolio. Shares added by 77.28%
5. Apellis Pharmaceuticals Inc (APLS) - 3,600,000 shares, 4.91% of the total portfolio. Shares reduced by 20.04%

Cormorant Asset Management, LLC initiated holding in ChemoCentryx Inc. The purchase prices were between $10.01 and $13.89, with an estimated average price of $11.44. The stock is now traded at around $12.35. The impact to a portfolio due to this purchase was 2.46%. The holding were 2,525,900 shares as of .

Cormorant Asset Management, LLC initiated holding in Galapagos NV. The purchase prices were between $89.61 and $117.78, with an estimated average price of $100.78. The stock is now traded at around $114.30. The impact to a portfolio due to this purchase was 2.45%. The holding were 300,000 shares as of .

Cormorant Asset Management, LLC initiated holding in Autolus Therapeutics PLC. The purchase prices were between $24.38 and $34.71, with an estimated average price of $28.56. The stock is now traded at around $23.90. The impact to a portfolio due to this purchase was 1.87%. The holding were 850,000 shares as of .

Cormorant Asset Management, LLC initiated holding in Atara Biotherapeutics Inc. The purchase prices were between $28.4 and $41.74, with an estimated average price of $37.18. The stock is now traded at around $24.85. The impact to a portfolio due to this purchase was 1.53%. The holding were 550,000 shares as of .

Cormorant Asset Management, LLC initiated holding in Myovant Sciences Ltd. The purchase prices were between $16.41 and $24.45, with an estimated average price of $20.37. The stock is now traded at around $13.51. The impact to a portfolio due to this purchase was 1.09%. The holding were 650,000 shares as of .

Cormorant Asset Management, LLC initiated holding in Gossamer Bio Inc. The purchase prices were between $17.58 and $23.97, with an estimated average price of $20.81. The stock is now traded at around $20.49. The impact to a portfolio due to this purchase was 0.99%. The holding were 653,129 shares as of .

Cormorant Asset Management, LLC added to a holding in InflaRx NV by 75.58%. The purchase prices were between $31.16 and $48.62, with an estimated average price of $37.15. The stock is now traded at around $41.60. The impact to a portfolio due to this purchase was 2.95%. The holding were 2,590,000 shares as of .

Cormorant Asset Management, LLC added to a holding in Ascendis Pharma A/S by 77.28%. The purchase prices were between $62.15 and $129.99, with an estimated average price of $86.75. The stock is now traded at around $121.81. The impact to a portfolio due to this purchase was 2.15%. The holding were 600,000 shares as of .

Cormorant Asset Management, LLC added to a holding in CRISPR Therapeutics AG by 800.00%. The purchase prices were between $28.02 and $40.87, with an estimated average price of $34.47. The stock is now traded at around $38.67. The impact to a portfolio due to this purchase was 2%. The holding were 900,000 shares as of .

Cormorant Asset Management, LLC added to a holding in Sarepta Therapeutics Inc by 233.33%. The purchase prices were between $106.67 and $151.68, with an estimated average price of $128.32. The stock is now traded at around $119.19. The impact to a portfolio due to this purchase was 1.75%. The holding were 300,000 shares as of .

Cormorant Asset Management, LLC added to a holding in Allakos Inc by 400.00%. The purchase prices were between $33.79 and $52.27, with an estimated average price of $40.54. The stock is now traded at around $41.65. The impact to a portfolio due to this purchase was 1.7%. The holding were 750,000 shares as of .

Cormorant Asset Management, LLC added to a holding in Biohaven Pharmaceutical Holding Co Ltd by 69.23%. The purchase prices were between $34.52 and $53.29, with an estimated average price of $43.04. The stock is now traded at around $61.78. The impact to a portfolio due to this purchase was 1.62%. The holding were 1,100,000 shares as of .

Cormorant Asset Management, LLC sold out a holding in Tesaro Inc. The sale prices were between $74.02 and $74.96, with an estimated average price of $74.7.

Cormorant Asset Management, LLC sold out a holding in Dicerna Pharmaceuticals Inc. The sale prices were between $9.74 and $14.65, with an estimated average price of $11.47.

Cormorant Asset Management, LLC sold out a holding in Theravance Biopharma Inc. The sale prices were between $22.57 and $28.15, with an estimated average price of $25.42.

Cormorant Asset Management, LLC sold out a holding in G1 Therapeutics Inc. The sale prices were between $14.4 and $21.45, with an estimated average price of $19.02.

Cormorant Asset Management, LLC sold out a holding in Replimune Group Inc. The sale prices were between $10 and $16.24, with an estimated average price of $12.42.

Cormorant Asset Management, LLC sold out a holding in ContraFect Corp. The sale prices were between $0.36 and $1.94, with an estimated average price of $0.56.

Cormorant Asset Management, LLC reduced to a holding in Mirati Therapeutics Inc by 38.63%. The sale prices were between $42.42 and $78.95, with an estimated average price of $67.65. The stock is now traded at around $63.50. The impact to a portfolio due to this sale was -2.38%. Cormorant Asset Management, LLC still held 1,075,000 shares as of .

Cormorant Asset Management, LLC reduced to a holding in Avrobio Inc by 77.91%. The sale prices were between $12.46 and $22.05, with an estimated average price of $15.23. The stock is now traded at around $18.40. The impact to a portfolio due to this sale was -1.46%. Cormorant Asset Management, LLC still held 300,000 shares as of .